Introduction {#s1}
============

Cellular growth and function depend heavily on protein synthesis, which is often considered a constitutive activity for a cell. However, it is becoming clear that global protein synthesis rates are not always static, that they vary widely among cell types, and that these differences are necessary for normal tissue development and homeostasis ([@bib8]). Particularly, the rate of protein synthesis in adult heart is one of the lowest amongst different tissues but increases markedly in response to stress and hypertrophic stimuli ([@bib17]; [@bib32]). The molecular basis for these historical observations, however, is still poorly understood.

Translation initiation is the rate-limiting step in protein synthesis ([@bib1]; [@bib22]; [@bib42]). Interactions between the 5' m^7^GpppN cap structure, the pre-initiation factors (including eIF4A, eIF4E, and eIF4G), and poly(A)-binding protein C1 (PABPC1) form a stable, looped mRNP complex ([@bib2]; [@bib16]; [@bib36]; [@bib38]; [@bib44]; [@bib49]) that stimulates translation while safeguarding the mRNA from exonucleases ([@bib10]; [@bib20]; [@bib23]; [@bib31]; [@bib50]). Based on these central roles, PABPC1 is thought to be ubiquitously expressed and serve 'house-keeping' roles in protein synthesis.

Here, we report that PABPC1 protein expression is post-transcriptionally silenced in adult human and mouse hearts through shortening of its mRNA poly(A) tail, which results in reduced polysome association and translation of *Pabpc1* transcripts. The developmental silencing of PABPC1 is cardiomyocyte-specific and reversible. We show that *Pabpc1* poly(A) tail length and protein expression are restored during adult-onset cardiac hypertrophy stimulated by endurance exercise or heart disease. Furthermore, we demonstrate that PABPC1 re-expression and its interaction with eIF4G are necessary and sufficient to globally stimulate translation and physiologic growth of cardiomyocytes. These findings reveal a novel, poly(A) tail-based regulatory mechanism in the heart that dynamically controls PABPC1 expression and subsequent protein synthesis in response to developmental and hypertrophic signals.

Results and discussion {#s2}
======================

The association of eIF4F complex with the 5' m^7^G cap structure is stabilized through eIF4G-PABPC1 interactions, which promote ribosomal recruitment and translation initiation ([@bib2]; [@bib16]; [@bib38]; [@bib44]; [@bib49]). We have discovered that PABPC1 protein levels in the adult mouse heart are drastically lower relative to the embryonic day (E)17 stage ([Figure 1A,B](#fig1){ref-type="fig"}). Parallel examination of *Pabpc1* mRNA abundance unexpectedly showed only a modest decrease after birth ([Figure 1B](#fig1){ref-type="fig"}). A similarly striking reduction in PABPC1 protein, but not mRNA levels, was observed in adult versus fetal human hearts indicating PABPC1 silencing is post-transcriptional and evolutionarily conserved ([Figure 1C,D](#fig1){ref-type="fig"}). We inspected PABPC1 mRNA and protein abundance in several other mouse and human tissues and determined that the postnatal silencing of PABPC1 is muscle-specific ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}). Coimmunofluorescent staining of PABPC1 with a cardiomyocyte marker (TNNT2) combined with immunoblot analyses of purified cell types revealed that while PABPC1 is abundantly expressed in all cells within the neonatal heart, it is selectively silenced in adult cardiomyocytes ([Figure 1E,J](#fig1){ref-type="fig"} and [Figure 1---figure supplements 1E](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}).10.7554/eLife.24139.003Figure 1.PABPC1 is dynamically regulated during cardiac development and hypertrophy.(**A--D**) Relative quantification of PABPC1 protein (immunoblots) and mRNA (qPCR) levels normalized to GAPDH during mouse heart and liver development (**A, B**) and in human fetal and adult hearts (**C, D**). (**E--J**) Immunofluorescent images of mouse postnatal day 0 (P0) and 8-week-old adult hearts stained for PABPC1 (red), cardiac troponinT (green), and DAPI (blue). Insets **G** and **J** show cardiomyocytes, while **F** and **I** show non-cardiomyocytes. Immunoblots and quantification of PABPC1 protein and mRNA from wild-type mouse hearts 8 weeks after (**K**) thoracic aortic constriction (TAC) or (**L**) 10-week exercise training. Data are mean ± s.d (n = 3); \*p\<0.05, unpaired two-tailed *t*-test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.003](10.7554/eLife.24139.003)10.7554/eLife.24139.004Figure 1---figure supplement 1.Post-transcriptional silencing of PABPC1 is muscle-specific.(**A**) Immunoblots for PABPC1 from postnatal day 0 (P0) and 8-week-old adult mice from the indicated tissue with GAPDH as a loading control. (**B**) Quantification of PABPC1 protein and mRNA expression (qPCR). Data are mean ± s.d (n = 3); \*p\<0.005 unpaired two-tailed *t*-test. (**C**) PABPC1 immuno-histochemistry images based on anti-PABPC1 antibody (Abcam ab21060) from the Human Protein Atlas Database ([www.proteinatlas.org](http://www.proteinatlas.org)) showing that PABPC1 is abundantly expressed in other adult tissues but not heart and skeletal muscle. (**D**) RPKM values from the Human Protein Atlas Database showing relative *Pabpc1* mRNA levels in various human tissues. (**E**) Western blot of purified P0 and adult cardiomyocytes (CMs) and cardiac fibroblasts (CFs). Blotting for Desmin (DES, CM marker) and Vimentin (VIM, CF marker) show clean separation of cell types.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.004](10.7554/eLife.24139.004)10.7554/eLife.24139.005Figure 1---figure supplement 2.Post-transcriptional silencing of PABPC1 is muscle-specific.Single-channel immunofluorescent images of mouse postnatal day 0 (P0) and 8-week-old adult hearts stained for PABPC1 (red), cardiac troponinT (green), and DAPI (blue).**DOI:** [http://dx.doi.org/10.7554/eLife.24139.005](10.7554/eLife.24139.005)

We sought to determine whether PABPC1 protein is re-expressed in the adult heart during hypertrophy, a condition accompanied by increased size of individual cardiomyocytes, enhanced protein synthesis, and induction of many fetal genes ([@bib21]; [@bib35]; [@bib45]). We used thoracic aortic constriction (TAC) and endurance exercise training in mice as models of pathologic and physiologic hypertrophy, respectively ([@bib12]; [@bib24]). PABPC1 protein levels were markedly induced under both conditions without any change in mRNA abundance ([Figure 1K,L](#fig1){ref-type="fig"}). These results illustrate that post-transcriptional silencing of PABPC1 in the adult heart is reversed during cardiac hypertrophy.

To probe whether the disappearance of PABPC1 protein in the adult heart is due to a reduction of synthesis, we conducted polysome profiling of E18 and adult mouse hearts ([Figure 2A](#fig2){ref-type="fig"}). Quantitative PCR (qPCR) analyses of fractionated lysates showed a significant shift of *Pabpc1* mRNAs away from polyribosomes to the mRNP/monosome fractions in the adult hearts, demonstrating reduced accessibility to the translational machinery in contrast to the E18 hearts. Control *Gapdh* mRNA remained associated with polyribosomes at both developmental stages ([Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.24139.006Figure 2.Poly(A) tail length determines cell-type and developmental stage-specific translation of PABPC1.(**A**). Polysome profile of embryonic day 18 (E18) and adult mouse hearts. (**B**) Percentage of *Pabpc1* and *Gapdh* mRNAs measured by qPCR in each fraction collected from the polysome profiling. (**C**) Neonatal and 8-week-old adult wild-type mice were pulsed with puromycin through an intraperitoneal injection. Forty-five minutes following injection, heart and liver tissues were harvested for immunoblotting with anti-puromycin antibody. De novo protein synthesis was quantified as the ratio of puromycin labeled peptides to total protein. (**D**) Fractional distribution of *Pabpc1* mRNAs with short and long poly(A) tails in whole heart, C2C12 cells, cardiomyocytes (CMs), cardiac fibroblasts (CFs), whole heart after TAC surgery, and whole heart after exercise (measured by qPCR following poly(A) tail fractionation). (**E**) Poly(A) tail length status of *Pabpc1* mRNA within P0 and adult heart RNP, monosome, and polysome fractions from sucrose gradients. (**F**) *Pabpc1* single-molecule RNA-FISH in C2C12 myoblasts and myotubes. Data are mean ± s.d (n = 3); \*p\<0.05, \*\*p*\<*0.005 unpaired two-tailed *t*-test; NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.006](10.7554/eLife.24139.006)10.7554/eLife.24139.007Figure 2---figure supplement 1.Regulation of PABPC1 expression in adult heart is independent of miRNAs or alternative splicing.Targeted deletion of *Dicer* in adult cardiomyocytes was obtained by treating 8-week-old *Dicer* f/f; MCM mice with tamoxifen (20 mg/Kg/day) for 5 consecutive days^21^. Forty-eight hours after the last injection, heart tissues were harvested. (**A**) Relative PABPC1 protein (immunoblots) or (**B**) mRNA (qPCR) levels were measured in the indicated samples. Fold change in PABPC1 protein was determined by relative quantification of band intensities, normalized to GAPDH (shown below the blots). Data are mean ± s.d (n = 3); unpaired two-tailed *t*-test. NS, not significant. (**C**) UCSC genome browser tracks of *Pabpc1* mRNA in cardiomyocytes and fibroblasts from neonatal and adult mice^16^.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.007](10.7554/eLife.24139.007)10.7554/eLife.24139.008Figure 2---figure supplement 2.Limited influence for 5' and 3' untranslated regions (UTRs) of *Pabpc1* on luciferase protein translation during C2C12 differentiation.(**A**) Representative immunoblot demonstrating a steady decrease in PABPC1 protein levels during C2C12 differentiation; p38 was used as a loading control. (**B**) Quantification of PABPC1 protein (immunoblots) and mRNA (qPCR) levels relative to p38 during C2C12 differentiation. (**C**) Schematic of the reporters designed to assess the effect of *Pabpc1* 5' and 3' UTRs on luciferase protein expression. (**D**) Relative luciferase activity derived from C2C12 cells transfected with different reporter constructs shows that only *Pabpc1* 5' UTR has a moderate effect (twofold) on the reporter activity in differentiated myotubes, whereas the 3' UTR and the combination of UTRs have no effects. Data are mean ± s.d (n = 3); \*p\<0.05, unpaired two-tailed *t*-test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.008](10.7554/eLife.24139.008)10.7554/eLife.24139.009Figure 2---figure supplement 3.Experimental design of northern blot and RNA isolation based on poly(A) tail length through gradient purification.(**A**) Oligo design for the *Pabpc1* northern assay. Oligos were designed for the *Pabpc1* mRNA to be targeted in an RNAseH digestion leaving 700nt downstream of the cleavage site and the native poly(A) tail. (**B**) Northern blot using a radiolabeled probe against *Pabpc1* from E18 and 8-week-old adult mouse hearts following RNAseH cleavage. In the final lane, oligo dT was also added to the RNAseH reaction so that the *Pabpc1* transcript was cleaved at both ends, leaving just the 700nt region. A similar RNAseH cleavage assay was used for GAPDH as a control. (**C**) Adult mouse heart total RNAs with and without RNAse T1 treatment were mixed with biotinylated oligo(dT) and bound to the streptavidin-conjugated beads. Different salt concentrations were used to elute mRNAs. The differing poly(A) tail lengths of eluted RNAs were checked by northern blot analysis using an oligo-dT40 probe. This served as optimizations for further purifications of short and long poly(A) tail RNAs that were subjected to qPCR analysis using gene-specific primers. (**D**) Poly(A) tail status of P0 and Adult *Gapdh* in polysome gradient fractions as a control experiment. *Gapdh* is enriched in the long-tailed and polysome fractions as expected.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.009](10.7554/eLife.24139.009)

Intriguingly, in comparison to E18, the adult heart polysome profiles exhibited a decrease in the number of polyribosomes with a corresponding increase of 80S monosomes, which reflects reduced translation efficiency ([Figure 2A](#fig2){ref-type="fig"}). To further quantify global protein synthesis rates in vivo, we pulse-labeled wild-type neonates and adult mice with puromycin followed by immunoblotting using an anti-puromycin antibody (i.e. SUnSET assays) ([@bib19]; [@bib39]). We detected a robust decrease in puromycin-labeled peptides in adult versus neonatal hearts but not in liver tissues ([Figure 2C](#fig2){ref-type="fig"}). Lower protein synthetic capacity of adult striated muscle compared to other tissues was first observed more than three decades ago ([@bib17]; [@bib32]). Our data showing muscle-specific silencing of PABPC1 thus offers a plausible molecular basis for these historical observations. Low-level protein synthesis in the absence of PABPC1 could presumably result from alternative mRNA circularization mechanisms ([@bib7]; [@bib34]; [@bib47]) or translation of some mRNAs in a closed loop-independent manner ([@bib3]; [@bib11]).

Next, we investigated the molecular mechanisms responsible for inefficient translation of PABPC1. It appears that suppressed PABPC1 translation in the adult heart is microRNA-independent, as we saw no change in PABPC1 protein or mRNA in tamoxifen-inducible, heart-specific adult *dicer* knockouts ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}), which are defective in microRNA processing ([@bib25]). We analyzed available RNA-sequencing data from neonatal and adult mouse cardiomyocytes and fibroblasts ([@bib18]) and found no evidence for alternative splicing or a developmental change in *Pabpc1* 5'- or 3'- untranslated regions (UTRs) in either cell types ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We reasoned that *trans*-acting factor(s) might bind to the sequence elements within *Pabpc1* UTRs to suppress its translation. To test this hypothesis, we constructed luciferase reporters fused to 5'-, 3'- or both mouse *Pabpc1* UTRs and transfected them into C2C12 myoblasts. C2C12 cells exhibit marked downregulation of endogenous PABPC1 protein (\~10 fold) but not mRNA levels when differentiated into myotubes ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). Amongst the different reporters, only *Pabpc1* 5'-UTR showed a modest (\<2-fold) decrease in luciferase (*Rluc*/*Fluc*) activity during myoblast-to-myotube differentiation ([Figure 2---figure supplement 2C,D](#fig2s2){ref-type="fig"}). Although PABPC1 binding to an A-rich element within its 5′-UTR could auto-regulate its translation ([@bib13]; [@bib27]), the relatively mild effects of 5'-UTR in reporter assays along with decreasing PABPC1 protein levels during muscle development argue against auto-regulatory feedback as the primary mechanism inhibiting *Pabpc1* translation.

Besides UTRs, poly(A) tail length is another major determinant for protein synthesis; mRNAs containing longer tails being more stable and translated more efficiently ([@bib14]; [@bib33]; [@bib48]). Therefore, we tested whether *Pabpc1* mRNAs are deadenylated in the adult heart. Both RNaseH cleavage assay and qPCR of long- and short-tailed mRNAs (fractionated by affinity chromatography) demonstrated significant *Pabpc1* deadenylation in adult versus E18 hearts and in myotubes versus myoblasts ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 3A--C](#fig2s3){ref-type="fig"}). *Pabpc1* poly(A) tail length in E18 hearts was estimated to be \~150 nucleotides (nts), whereas it was reduced to \~20 nts in adult hearts ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}). *Gapdh* poly(A) tail length was measured as a control and showed no difference between E18 and adult hearts. Importantly, shortening of *Pabpc1* poly(A) tail in the adult heart was cardiomyocyte-specific; and partly reversed after TAC or endurance exercise ([Figure 2C](#fig2){ref-type="fig"}). In addition, *Pabpc1* poly(A) tail length was strongly correlated to its association with monosomes and polysomes. At P0, *Pabpc1* mRNAs were almost exclusively long-tailed and in polysomes, whereas adult *Pabpc1* fractionated majorly into short-tailed and monosome fractions ([Figure 2E](#fig2){ref-type="fig"}). *Gapdh* poly(A) tail length remained unchanged and primarily associated with polysomes at both developmental stages ([Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). We further explored if inhibition of *Pabpc1* translation could be due to nuclear retention of *Pabpc1* transcripts. Single-molecule RNA FISH, however, showed primarily cytoplasmic staining without any noticeable difference in *Pabpc1* mRNA localization between myoblasts and myotubes indicating poly(A) tail status does not impact *Pabpc1* nucleo-cytoplasmic export in these cells ([Figure 2F](#fig2){ref-type="fig"}). Together, these results provide compelling evidence that *Pabpc1* poly(A) tail length is dynamically regulated during cardiac development and hypertrophy, and that poly(A) tail shortening limits *Pabpc1* mRNA translation in the adult heart.

Because PABPC1 is upregulated in hypertrophy, we tested whether it is required for stimulus-induced growth of cardiomyocytes. PABPC1-depleted neonatal mouse cardiomyocytes were viable but resistant to isoproterenol (Iso) or triiodothyronine (T3)-induced hypertrophy ([Figure 3A--I](#fig3){ref-type="fig"}). Metabolic labeling of cardiomyocytes with an alkyne-modified glycine analog, L-homopropargylglycine (HPG), to measure newly synthesized proteins revealed that PABPC1 knockdown inhibited the normal surge in protein synthesis rate evoked by Iso or T3 stimulation ([Figure 3J,K](#fig3){ref-type="fig"}). Furthermore, we found that PABPC1 deficiency blocked protein but not mRNA upregulation of the hypertrophic markers *Acta1*, *Myh7* and *Anp* ([Figure 3L,M](#fig3){ref-type="fig"}) indicating that while new protein synthesis is impaired, the transcriptional response to hypertrophic stimuli is still functional in these cells ([@bib26]; [@bib40]). These results demonstrate that PABPC1 depletion does not affect the transcriptional regulatory circuits or mRNA stability of these hypertrophy markers.10.7554/eLife.24139.010Figure 3.Knockdown of PABPC1 in neonatal mouse cardiomyocytes prevents stimulus-induced hypertrophy and protein synthesis.(**A--F**) Primary cardiomyocytes isolated from newborn mice were transfected with siRNA against control *Luciferase* or *Pabpc1*. Twelve hours following transfection, cells were treated with isoproterenol (Iso) or triiodothyronine (T3) for 36 hr to induce hypertrophy. Cells were stained for Desmin and Actin by immunofluorescence to verify cardiomyocyte identity and measure cell area. (**G, H**) Immunoblots demonstrating efficient PABPC1 knockdown 48 hr after siRNA treatments with either Iso or T3. (**I**) Quantification of cell area 36 hr post Iso or T3 treatments. (**J, K**) Measurement of new protein synthesis using Click-iT homopropargylglycine assay after 2 hr of Iso or T3 treatments. (**L**) Quantification of mRNA (qPCR) from neonatal cardiomyocytes for each condition shows significant upregulation of mRNA for *Acta1*, *Myh7*, and *Anp* in response to Iso or T3 treatments. (**M**) Representative immunoblot showing that protein levels of ACTA1, MYH7, and ANP are increased after Iso or T3 treatments in the control *Luciferase* knockdown but synthesis is prevented when *Pabpc1* is knocked down. Data are mean ± s.d (n = 3); \*p\<0.05, \*\*p\<0.01, one-way analysis of variance (ANOVA) plus Dunnett's post-hoc test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.010](10.7554/eLife.24139.010)10.7554/eLife.24139.011Figure 3---source data 1.Source data for cell area of cultured neonatal cardiomyocytes treated with siRNA and either Iso or T3.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.011](10.7554/eLife.24139.011)

PABPC1 contains four RNA recognition motifs (RRM1-4), a linker region and a C-terminal MLLE domain ([@bib20]). While all four RRMs are capable of binding to poly(A) RNA, RRM2 preferentially interacts with eIF4G to stimulate cap-dependent translation ([@bib38]). Hence, we investigated if PABPC1 interactions with eIF4G are necessary for triggering cardiomyocyte hypertrophy and new protein synthesis. The M161A mutation was previously shown to disrupt PABPC1 interactions with eIF4G ([@bib23]). However, we decided to use the recently available structural information ([@bib38]) to engineer additional mutations within the RRM2 domain of PABPC1 to completely abolish its interactions with eIF4G ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). We confirmed that although PABPC1~mRRM2~ fails to interact with eIF4G1 in coimmunoprecipitation and in vitro binding assays, it binds to poly(A) RNA with similar affinities as wild-type PABPC1 ([Figure 4---figure supplement 1B--F](#fig4s1){ref-type="fig"}).

Next, we carried out rescue experiments wherein endogenous PABPC1 in cardiomyocytes was silenced using a 3'-UTR-targeted siRNA followed by adenoviral transduction of GFP, siRNA-resistant wild type, or PABPC1~mRRM2~ cDNAs ([Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}). Supplementing PABPC1-deficient cardiomyocytes with wild type PABPC1 re-sensitized the hypertrophic growth response to Iso ([Figure 4A--M](#fig4){ref-type="fig"}), reversed the block in new protein synthesis ([Figure 4N--P](#fig4){ref-type="fig"}) and restored translation of hypertrophic markers in these cells ([Figure 4Q](#fig4){ref-type="fig"}). PABPC1~mRRM2~, however, failed to rescue any of these phenotypes ([Figure 4A--Q](#fig4){ref-type="fig"}) underscoring that PABPC1**--**eIF4G interactions are essential to evoke cardiomyocyte hypertrophy and stimulate translation in response to hypertrophic signals.10.7554/eLife.24139.012Figure 4.PABPC1--eIF4G1 interactions control stimulus-induced new protein synthesis and hypertrophy.(**A--L**) Representative images of neonatal cardiomyocytes infected with adenovirus expressing GFP, wildtype PABPC1, or a PABPC1 RRM2 mutant (that does not interact with eIF4G1), transfected with siRNA against endogenous *Pabpc1* or *Luciferase*, and treated with isoproterenol (Iso) or vehicle (Veh). Quantification of (**M**) cell areas, (**N**) total protein content, (**O, P**) rate of new protein synthesis measured by Click-iT homopropargylglycine fluorescence assay after respective treatments. (**Q**) Representative immunoblots of hypertrophy markers. Data are mean ± s.d (n = 3); \*p\<0.05, one-way analysis of variance (ANOVA) plus Dunnett's post-hoc test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.012](10.7554/eLife.24139.012)10.7554/eLife.24139.013Figure 4---source data 1.Source data for cell area of cultured neonatal cardiomyocytes after treatment with siRNA, adenovirus, and Iso.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.013](10.7554/eLife.24139.013)10.7554/eLife.24139.014Figure 4---figure supplement 1.PABPC1~mRRM2~ can bind to poly(A) RNA but does not interact with eIF4G1.(**A**) Schematic of the PABPC1 protein with key domains labeled. Mutations of the RRM2 domain (PABPC1~mRRM2~) with eight amino acid replacements to interrupt PABPC1-eIF4G binding were made using the available structural information^5^. (**B**) C2C12 myoblasts were infected with FLAG-PABPC1, FLAG-PABPC1~mRRM2~, and control GFP adenoviruses followed immunoprecipitation by anti-FLAG antibody and blotting for endogenous eIF4G1. FLAG-PABPC1 construct efficiently immunoprecipitated eIF4G1, whereas the negative control FLAG-GFP and the PABPC1~mRRM2~ did not. (**C**) Constructs used for bacterial expression and purification for mouse PABPC1, PABPC1~mRRM2~, and a PABP-interacting fragment of mouse eIF4G1^5^. (**D**) Equimolar amounts of purified His-eIF4GI ~61-225~ and GST-PABPC1 or GST-PABPC1~mRRM2~ were mixed and incubated with or without RNase A. Protein complexes were isolated using Glutathione-Magnetic beads, separated on 10% SDS-PAGE gel and visualized by Coomassie staining. GST-PABPC1 showed binding to His-eIF4GI ~61-225~ whereas GST-PABPC1~mRRM2~ or empty beads did not. (**E**) A gradient of concentrations of GST, GST-PABPC1~mRRM2~, and GST-PABPC1 along with ^32^P labeled poly(A)~25~ oligo were used to capture Protein-RNA probe complexes and un-bound RNA probes respectively in a filter binding assay. Following incubation, radioactive signal was measured to quantify how much ^32^P-poly(A)~25~ remained bound to the protein and how much washed through to the nucleic acid membrane. GST did not bind any ^32^P-poly(A)~25~. Both wild-type and mutant PABPC1~mRRM2~ were capable of binding the ^32^P-poly(A)~25~. (**F**) Quantification of the Geiger counts on the protein membrane. (**G**) Schematic depicting the experimental set up of PABPC1 rescue experiments in neonatal cardiomyocytes.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.014](10.7554/eLife.24139.014)

To further determine if PABPC1 upregulation is sufficient to drive cardiac hypertrophy, we generated a doxycycline-inducible, cardiomyocyte-specific PABPC1 transgenic mouse model ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Ectopic expression of FLAG-tagged PABPC1 protein in adult mouse hearts showed the expected cytoplasmic distribution ([Figure 5E,F](#fig5){ref-type="fig"}) and was estimated approximately 12-fold higher over endogenous levels ([Figure 5---figure supplement 1C,D](#fig5s1){ref-type="fig"}). Remarkably, forced PABPC1 expression in the adult myocardium led to increased atrial and ventricular size ([Figure 5A--D](#fig5){ref-type="fig"}), a significant elevation in heart-to-body weight ratios, and larger cardiomyocyte cross-sectional areas compared to uninduced littermate controls ([Figure 5G--J](#fig5){ref-type="fig"}). We also observed significant increase in global protein synthesis rates along with upregulation of many physiological but not pathological hypertrophic markers in PABPC1 transgenic hearts ([Figure 5K,L](#fig5){ref-type="fig"}). Notably, PABPC1 transgenic mice did not exhibit premature lethality or cardiac dilation even when induced for 6 months. Moreover, long-term PABPC1 induction did not cause a drop in performance in treadmill tests, deterioration in cardiac contractility, or deficits in systolic and diastolic function ([Figure 5---figure supplement 1E,F](#fig5s1){ref-type="fig"}). Also, histologically, we did not observe any myofiber disarray or fibrosis ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) suggesting hypertrophy in these animals is compensated and does not progress to heart failure, but rather mimics the physiologic form.10.7554/eLife.24139.015Figure 5.Forced expression of PABPC1 in adult cardiomyocytes induces physiologic hypertrophy.(**A--H**) Representative whole heart, H&E, immunofluorescent, and WGA-stained sections of 2-week doxycycline (Dox)-induced MHCrtTA transgenic controls and TRE-PABPC1; MHCrtTA bitransgenic mice. (**I**) Heart-to-body weight ratios (n = 6). (**J**) Cell area quantified from WGA-stained sections (n = 3). (**K**) Global rate of translation based on puromycin incorporation in hearts of injected mice (n = 6). (**L**) Relative mRNA levels of indicated physiological and pathological hypertrophy markers normalized to GAPDH (qPCR, n = 9). Data are mean ± s.d; \*p\<0.05 unpaired two-tailed *t*-test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.015](10.7554/eLife.24139.015)10.7554/eLife.24139.016Figure 5---source data 1.Source data for cardiomyocyte areas performed on WGA stained heart tissue sections of 2-week doxycycline-induced MHCrtTA transgenic controls and TRE-PABPC1; MHCrtTA bitransgenic mice.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.016](10.7554/eLife.24139.016)10.7554/eLife.24139.017Figure 5---source data 2.Source data for [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.Sheet 1: Source data for exercise performance between 6-month doxycycline induced MHCrtTA transgenic controls and TRE-PABPC1; MHCrtTA bitransgenic mice. Sheet 2: Source data for cardiac function tests between 6-month doxycycline-induced MHCrtTA transgenic controls and TRE-PABPC1; MHCrtTA bitransgenic mice.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.017](10.7554/eLife.24139.017)10.7554/eLife.24139.018Figure 5---figure supplement 1.Generation of tetracycline-inducible, heart-specific PABPC1 transgenic mouse model.(**A**) The TRE-PABPC1 construct expresses mouse PABPC1 containing an N-terminal Flag tag driven by a TRE and a CMV minimal promoter. TRE-PABPC1 mice were mated with *Myh6*-rtTA (MHCrtTA) mice to generate TRE-PABPC1; MHCrtTA bitransgenic mice as shown. Eight-week-old adult bitransgenic and MHCrtTA control animals were fed 2 g/kg doxycycline (Dox) containing diet for 2 weeks to induce FLAG-PABPC1 expression specifically in cardiomyocytes. (**B**) Immunoblot against FLAG shows that exogenous PABPC1 in the heart is only expressed when Dox is present in the diet. (**C**) Immunoblot against PABPC1 shows the relative amount of induction relative to the wild-type mice. (**D**) Quantification of the blot in **C** Data are mean ± s.d (n = 6); \*p\<0.05, unpaired two-tailed *t*-test. (**E**) MHCrtTA control and bitransgenic mice were induced with 2 g/kg Dox diet for 6 months and then subjected to acute exercise performance test to measure effects of PABPC1 expression on relative Max VO~2~ consumption, distance traveled, or work completed. (**F**) Echocardiograms were performed to calculate ejection fraction (EJ), fractional shortening (FS), and left ventricular internal dimension at systole and diastole (LVID). Data are mean ± s.d (n = 6--12); \*p\<0.05, unpaired two-tailed *t*-test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.018](10.7554/eLife.24139.018)10.7554/eLife.24139.019Figure 5---figure supplement 2.Induced expression of cardiomyocyte specific PABPC1 does not lead to damage.Histological sections of 6-month 2 g/kg doxycycline (Dox)-induced MHCrtTA transgenic and TRE-PABPC1; MHCrtTA bitransgenic mice. Hematoxylin and eosin or trichrome staining shows normal cytoarchitecture of the heart, no myofiber disarray or presence of inflammatory cells, and no signs of damage or interstitial fibrosis in either genotype. Immunohistochemistry with Ki67 antibody shows absence of any proliferating cells with PABPC1 overexpression.**DOI:** [http://dx.doi.org/10.7554/eLife.24139.019](10.7554/eLife.24139.019)

In conclusion, we have uncovered that poly(A) tail length shortening suppresses *Pabpc1* mRNA translation in mature cardiomyocytes, thereby reducing overall protein synthesis rates in the adult heart. Intriguingly, despite having a short poly(A) tail, *Pabpc1* transcripts remain stable and are not completely deadenylated or degraded. This might be due to binding of *trans*-acting factor(s), the presence of RNA structural element(s), or RNA modifications that act to stabilize *Pabpc1* in adult cardiomyocytes ([@bib31]). We further demonstrate that PABPC1 protein expression and poly(A) tail length are partially restored during adult-onset cardiac hypertrophy to activate new protein synthesis and physiologic growth of cardiomyocytes. PABPC1 was also shown to be both necessary and sufficient to drive cardiomyocyte hypertrophy. Thus, dynamic control of PABPC1 serves an adaptive role in stimulating a beneficial form of cardiac hypertrophy that may be physiologically advantageous to the failing or dilated myocardium.

Two genome-wide studies found a weak correlation between poly(A) tail lengths and translational efficiency of mRNAs in cell culture ([@bib9]; [@bib43]). While Subtelny et al. observed clear coupling between poly(A) tail length and translation at early developmental stages in *Xenopus* and zebra fish, the association became less apparent in the adults. Thus, it is plausible that at steady states, poly(A) tail length is less critical for translation but becomes a determinant in certain tissue contexts, developmental stages, cell cycle regulation, daily rhythmic oscillations of protein synthesis, or cellular stress ([@bib4]; [@bib30]; [@bib37]). Furthermore, stronger relationships between poly(A) tail length and mRNA translatability may emerge under conditions where PABPC1 protein concentrations are limiting; our data from adult cardiomyocytes supports this hypothesis.

Taken together, our findings not only provide insight into the long-standing question of how the heart regulates protein synthesis during development and hypertrophy but also provide a new direction to explore therapeutic interventions. These results set the stage for elucidating the signaling cascades that regulate *Pabpc1* poly(A) tail length in cardiomyocytes, determining mechanistically how those dynamics are achieved, and probing the general roles for poly(A) tail length in translation control within the heart and other somatic tissues.

Materials and methods {#s3}
=====================

Animal models and human samples {#s3-1}
-------------------------------

Mouse PABPC1 cDNA containing an N-terminal FLAG-tag was expressed from a transgene with a TRE/minimal CMV promoter, a genomic fragment including α -MHC untranslated exons 2 and 3 with intron 2 ([@bib28]), the *Pabpc1* ORF and the bovine growth hormone polyadenylation site and 3′ flanking genomic segment for proper mRNA 3′ end formation. The linearized transgene construct was subjected to pronuclear injection using standard methods to generate PABPC1 transgenic mice that were maintained on an FVB background. MHC-rtTA transgenic mice (FVB/N-Tg(*Myh6*-rtTA)1Jam) expressing a codon-optimized rtTA variant specifically in heart were commercially obtained (RRID: [MMRRC_010478](https://scicrunch.org/resolver/MMRRC_010478)) ([@bib46]). All mice reported were the F1 progeny of TRE-PABPC1 and MHC-rtTA matings and were, therefore, hemizygous for one or both transgenes. PABPC1 expression in 8- to 12-week-old bitransgenic animals was induced through doxycycline (Dox) in the food (2g Dox/kg food, Harlan, KY). Cardiac-specific *Dicer* knockouts were generated by crossing *Dicer^f^*^/f^ mice, with Tam-inducible MerCreMer transgenic mice as previously reported ([@bib25]). DNA was extracted from tail clips using DirectPCR lysis reagent (Viagen Biotech, Los Angeles, CA) and genotyped by PCR using transgene-specific primers ([Supplementary file 1](#SD5-data){ref-type="supplementary-material"}). Both male and female mice and littermate controls were used whenever possible. Human fetal (22-week old) and adult (51-year-old Caucasian male) heart RNAs and proteins were purchased from Clonetech Laboratories, Inc., Mountain View, CA We followed the NIH guidelines for use and care of laboratory animals, and all experimental protocols were approved by IACUC (Institutional Animal Care and Use Committee at University of Illinois, Urbana-Champaign.

Maximal aerobic exercise test to estimate VO~2max~ {#s3-2}
--------------------------------------------------

Mice performed an exhaustive acute exercise bout on a motorized treadmill (Columbus Instruments, Columbus, OH) to determine exercise capacity in Dox-induced TRE-PABPC1 × MHC-rtTA (n = 15) and control MHCrtTA (n = 13) mice using a previously validated equation ([@bib15]). Prior to the maximal exercise test, mice were acclimated to treadmill running for 2 concurrent days with the following protocol: warm-up 5 min at 8 m/min, 5 min exercise at 10 m/min, and 5 min cool-down at 8 m/min at 0% incline. Three days later, mice performed an exhaustive, incremental exercise bout that began at 11 m/min and increased 1 m/min every 2 min until exhaustion as previously described ([@bib12]). VO~2~ was determined for each stage using the following equation:

$Predicted\,\, VO_{2}(ml/min) = 0.127 \times weight(g) + (0.040 \cdot running\,\, speed(m/min)) - 0.974$

Exhaustion was determined if mice failed to continue running after spending 5 s off of the treadmill bout and not responding to manual stimulation. The researcher evaluating exhaustion was blinded to mouse genotype.

Exercise training protocol {#s3-3}
--------------------------

PABPC1 expression was determined in the hearts of exercise trained C57BL6/J from a previous study ([@bib12]). Six-week-old C57BL6/J mice were randomized into sedentary (SED, n = 12) or endurance trained (EX, n = 10) groups and performed a progressive exercise training program on a motorized treadmill (Columbus Instruments, Columbus, OH). Mice were trained 3 days/ week (M/W/F) for 8 weeks. The exercise protocol consisted of: 10-min warm-up at 12 m/min, 45-min training period that began at 14 m/min (week 1) that increased to a speed of 22 m/min (week 8), and 5-min cool-down at 10 m/min. Mice were trained at the same time each day and sedentary mice were placed onto the treadmill to mimic the stress of handling and treadmill exposure.

Cardiac function tests {#s3-4}
----------------------

Transthoracic echocardiography was performed on lightly anesthetized mice using 1.5% isoflurane mixed with 95% oxygen as previously reported ([@bib25]). Mice were stabilized on a heated platform and taped to ECG electrodes. Evaluation of cardiac function was done using a Visual Sonics Vivo 770 ultra sound using a 30 MHz probe. Two-dimensional guided M-mode tracings were recorded in both parasternal long and short axis views at the level of papillary muscles. Image analysis was done using Visual Sonics software version 2.3.0.

Histology and immunohistochemistry {#s3-5}
----------------------------------

Heart tissues from doxycycline-induced MHCrtTA (*n* = 3) transgenic and TRE-PABPC1; MHCrtTA bitransgenic mice (*n* = 3) were harvested and fixed overnight in 10% neutral-buffered formalin, embedded in paraffin, and sectioned (3 μm thickness). Hematoxylin and eosin (H&E) and trichrome stainings were performed using standard histological methods as previously described ([@bib5]). For immunohistochemistry, unstained slides were deparaffinized in xylene (two treatments, 5 min each), rehydrated sequentially in ethanol (2 min each in 100%, 95%, and 80%), and washed for 3 min in water. Antigen retrieval was performed by boiling the sections in Tris buffered solution (20 mM Tris-Cl pH 9, 1 mM EDTA, 0.02% Tween 20) for 20 min at 111°C in a steam cooker then cooled for 20 min under tap water. For ki-67 staining, the endogenous peroxidase activity was quenched with a solution of 3% hydrogen peroxide solution (Fisher Scientific). After washing, sections were blocked (2% normal goat serum, 1% bovine serum albumin (BSA), 0.1% Triton X-100, 0.05%Tween 20 in 1X \~ PBS) for 30 min and incubated with primary anti-Ki-67 antibody at 4°C for 12 hr. After several washes, sections were incubated with HRP-conjugated goat anti-mouse IgG light-chain-specific antibody for 2 hr. For visualization of signal, DAB kit (Vector Labs) was used according to the manufacturer's instructions. All intermediate washing steps were done using 1X PBS, 0.5% Tween 20, pH 7.2 (1X PBST), and all antibodies were diluted in 1X PBST with 1% bovine serum albumin. Slides were sealed with a coverslip after lightly counterstaining with hematoxylin and photographed with an EVOS XL microscope. Wheat germ agglutinin stain (WGA, *L4895 SIGMA*) was used to stain heart cross-section according to manufacturer's instructions.

In vivo SUnSET assay {#s3-6}
--------------------

Proteins were labeled using a protocol adapted from the SUnSET method ([@bib19]; [@bib39]). P0 and Adult mice were injected with puromycin made in sterile PBS (0.04 μmol/ per g of body weight). After 45 min hearts and liver were harvested and protein lysates were prepared. Proteins were separated by 10% SDS-PAGE. Puromycin-labeled peptides were identified using the mouse monoclonal antibody 12D10 (1: 5000 dilution). Protein synthesis levels were determined by densitometry analysis of whole lanes. Normalization of the free puromycin was analyzed as previously described ([@bib19]).

Polysome gradient fractionation {#s3-7}
-------------------------------

Whole hearts (pooled batches of 2 to 3 hearts) were extracted and washed in ice-cold PBS containing cyclohexamide. Blood was removed by squeezing the heart with blunt forceps and quickly pulverized under liquid nitrogen using previously cooled, RNAse free mortar and pestle. The powder obtained was transferred to a 10 cm plate, previously cooled on dry ice for 10 min. Afterward, 1 mL of lysis buffer (10 mM Tris-HCl at pH 8.0, 150 mM NaCl, 5 mM MgCl2, 1% Nonidet-P40, 40 mM dithiothreitol, 500 U/mL RNAsin \[Promega\], 40 mM VRC \[New England Bio Labs\]) supplemented with 1% deoxycholate \[Fluka\] was added to the tissue powder. Next, re-suspended powder was scraped from the plate and transferred to a 2-mL tube with pipetting 10x to lyse the cells. The cell nuclei were removed by centrifugation (12,000 *g*, 10 s, at 4°C), and the supernatant was supplemented with 500 μL of 2X extraction buffer (0.2 M Tris-HCl at pH 7.5, 0.3 M NaCl), 150 μg/mL cycloheximide, 650 μg/mL heparin, and 10 mM phenyl-methylsulfonyl fluoride, and centrifuged (12,000 *g*, 5 min, at 4°C) to remove mitochondria and membranous debris. The supernatant was layered onto a 10 mL linear sucrose gradient (15%--45% sucrose \[w/v\], supplemented with 10 mM Tris-HCl at pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, 10 mM dithiothreitol, 100 μg/mL cycloheximide, 0.5 mg/mL heparin) and centrifuged in a SW41Ti rotor (Beckman) for 120 min at 38,000 rpm and 4°C, with the brake off. Polysome profiles were recorded using a UA-6 absorbance (ISCO) detector at 254 nm. Fractions (12 × 1 mL) were collected and RNAs were recovered by extraction with an equal volume of Trizol. RNAs were reverse transcribed using random hexamer primers and Maxima Reverse Transcriptase kit (Thermo Scientific). The cDNA was diluted to 25 ng/μL with nuclease free water and used for gene-specific qPCR assays.

Protein isolation and western blot analysis {#s3-8}
-------------------------------------------

Proteins from hearts or purified cell fractions were isolated as previously described ([@bib5]). In brief, frozen heart tissue or purified cell fractions were homogenized with cold homogenization buffer (10 mM HEPES-KOH, pH 7.5, 0.32 M Sucrose, 5 μM MG132, 5 mM EDTA-free Proteinase inhibitor \[Pierce 88666, Thermo Fisher\]) using a bullet blender (Next Advance). Samples were sonicated in the presence of 0.1% SDS and clarified by centrifugation (20,000 rcf at 4°C). The protein content was measured using the BCA protein assay kit (Thermo Scientific). Protein lysates (100--150 μg of protein loaded per lane) were resolved by 10% SDS-- polyacrylamide gel electrophoresis gels and transferred onto PVDF membranes (Immobilon, Millipore). Membranes were blocked in Tris-buffered saline (TBS) containing 5% non-fat dry milk and 0.2% Tween 20 (TBST), prior to incubation with primary antibody. The membranes were then washed with TBST followed by incubation with an appropriate horseradish peroxidase-conjugated secondary antibody for 2 hr. Blots were treated with Clarity Western ECL kit, visualized on a ChemiDoc XRS+ (BioRad), and quantified using Image Lab Software (RRID: [SCR_014210](https://scicrunch.org/resolver/SCR_014210)) according to standard procedures with experimental bands normalized to a control protein. Please refer to supplementary information for product numbers and Research Resource Identifiers of antibodies used in this study ([Supplementary file 1](#SD5-data){ref-type="supplementary-material"}).

Primary cardiomyocyte isolation {#s3-9}
-------------------------------

Cardiomyocytes and cardiac fibroblasts at specified time points were isolated from FVB/NJ wild-type mice as previously reported ([@bib18]). Briefly, neonatal cardiomyocytes were isolated with a neonatal rat/mouse cardiomyocyte isolation kit (Cellutron Life Tech Highland Park, NJ, USA; nc-603^1^) using manufacturer's instructions. Cells from 24 to 36 hearts were pooled, pre-plated for 2 hr on an uncoated dish to separate fibroblasts from cardiomyocytes. The supernatant containing the cardiomyocytes was removed, plated on SureCoat (Cellutron Life Tech; sc-9035) coated plates, and incubated at 37°C in a humidified incubator with 5% CO2. After 12 hr, media was changed to NW (Cellutron Life Tech; m-8032) and cultured until use. The purity of cultures was determined by Western blot as well as immunofluorescence staining with anti-Desmin (Abcam, ab15200) and anti-Vimentin (Abcam, 11256) antibodies. The plate containing fibroblasts was washed with PBS three times before extracting protein/RNA. Adult cardiomyocytes were isolated from 2-month-old FVB mice using a Adumyt Cardiomyocyte Isolation Kit (Cellutron Life Technology, ac-7034) according to the manufacturer\'s instructions. Mice were treated with anticoagulant (500 U heparin i.p.) 30 min prior to heart extractions. Langendorf perfusion was carried out at 37°C. Cardiomyocytes and fibroblasts were separated using the same pre-plating method as described above.

siRNA experiments and isoproterenol or T3 treatment {#s3-10}
---------------------------------------------------

To evaluate the role of PABPC1 proteins in cardiac hypertrophy, isolated neonatal cardiomyocytes were cultured in serum containing NS media (Cellutron Life Tech) for 12 hr. After 12 hr, the cells were washed twice with pre-warmed Serum-free media (NW, Cellutron Life Tech) before transfecting with the siRNA against endogenous *Pabpc1* ORF or 3'- UTR using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher). siRNA against *Luciferase* was used as control. After 12 hr, cells were washed with NW media and treated with 20 nM isoproterenol (Iso) or 20 ng of triiodothyronine (T3) and cultured for additional 36 hr.

Cell culture and RNA extraction {#s3-11}
-------------------------------

C2C12 cells (ATCC, CRL-1772; RROD: CVCL_0188) were cultured in DMEM (Dulbecco\'s Modified Eagle\'s Medium) supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin and were maintained at 37°C in 5% CO2 as previously descried ([@bib41]). The C2C12 cells were seeded in six-well plates. After 12--16 hr, when cell confluence reached approximately 100% the differentiation of C2C12 myoblasts into myotubes was induced by the addition of differentiation medium (DMEM containing 2.5% horse serum). Starting at the beginning of differentiation, the C2C12 cells were cultured in six-well plates and harvested for RNA extraction at 0, 1, 2, 3, and 4 days after differentiation. Total RNA samples were extracted using TRIZOL (Invitrogen) according to the manufacturer\'s instructions. Upon DNAse treatment (Promega), RNAs (\~2.5 μg) were reverse transcribed using random hexamer primers and Maxima Reverse Transcriptase kit (Thermo Scientific). The cDNA was diluted to 25 ng/μL with nuclease-free water and used for downstream qPCR assays.

Luciferase assay {#s3-12}
----------------

The 3' UTR of *Pabpc1* was cloned at the Not1 and Xho1 site of the psiCheck2 plasmid (downstream of RLuc). The 5' UTR of *Pabpc1* was cloned at Nhe 1 site (Upstream of RLuc). The double clone included both 5'UTR and 3'UTR and were cloned in their respective sites (Upstream and downstream of RLuc). C2C12 cells were plated on six-well plates at approximately 90--100% confluency and reverse transfections were performed using Mirus-Trans 20 reagent according to slightly modified manufacturer's protocol. Briefly, we transfected 3--5 μg of the respective plasmid at very high density of cells. The media was replaced after 24 hr of transfection with fresh low-serum differentiation media and cultured for 5 days before determination of luciferase activities using the Dual-Luciferase system. The Firefly and Renilla luciferase activities were measured at 24 hr after transient transfection for myoblast and 5 days after changing to low-serum differentiation media for myotube using the Dual-Glo Luciferase assay system (Promega) according to the manufacturer\'s instructions. Each plasmid was tested in three independent experiments. Luciferase activity was normalized using the Firefly luciferase activity levels and expressed as relative luciferase units (RLU) to reflect the influence of 5' UTR and 3'UTR activity on translation of Renilla luciferase.

In vitro binding assays {#s3-13}
-----------------------

The PABPC1-binding domain of eIF4G1 (residues 161--225) was cloned into the pET41a vector. The ORF of PABPC1 and PABPC1~mRRM2~ were cloned into the pGX-2T vector to be expressed as N-terminal 6X His-tagged and C-terminal GST tagged fusion proteins respectively in *E. coli* BL21 (strain α-DE3). Cells expressing GST-fusion proteins were lysed in PBS (19 mM Na2HPO4, 0.9 mM KH2PO4, 2.5 mM KCl, 140 mM NaCl \[pH 7.4\]) and the proteins were purified by affinity chromatography on glutathione-magnetic beads (Thermo Fisher, 88821). Cells expressing His-tagged proteins were lysed in lysis buffer (20 mM Tris-Cl, 300 mM NaCl, 1% NP40. pH-7.4), and the proteins were purified by affinity chromatography on Ni^2+^-NTA (Qiagen, 30230). The beads were washed using lysis buffer supplemented with 20 mM imidazole then eluted in 300 mM Imidazole buffer (20 mM Tris-Cl, 300 mM Imidazole, 10% Glycerol, 300 mM NaCl, pH 7.4). Equimolar amounts of His-eIF4GI~(161-225\ a.a)~ and GST-PABPC1 or GST-PABPC1~mRRM2~ were mixed and incubated with or without RNase A in 1XPBS for 3 hr at 4°C. Protein complexes were separated using Glutathione-Magnetic beads by incubating for 2 hr at 4°C. For control, purified GST protein was incubated with His-eIF4GI~(161-225\ a.a)~. Magnetic beads with the protein complex were washed with ice cold 1X PBS and directly boiled in 2X laemmli buffer before separating on 10% SDS-PAGE gel. The protein complexes were visualized using Coomassie stain.

Poly(A)-RNA-binding assay {#s3-14}
-------------------------

Poly(A)25 RNA (IDT) was radiolabeled at the 5' end with 50 mCi γ−32P-ATP using T4 polynucleotide kinase (NEB). For filter binding assays, 1 fmol of ^32^P-poly(A)25 was incubated with purified GST, GST-PABPC1, or GST-PABPC1mRRM2 in a final volume of 100 µL (Tris-HCl buffer (pH 8.0),70 mM KCl, 10% glycerol, 0.05% IGEPAL, 1 mM DTT, 100 ng/mL BSA supplemented with 0.4 unit/mL RNasin). The reaction was incubated at 40°C for 3 hr on a 96-well dot-blot (Minifold I; Schleicher & Schuell Cat.10447900). A Hybond N+ nylon membrane was placed beneath a Amersham Hybond ECL Nitrocellulose Membrane and pre-equilibrated with 1X TBE. These membranes, used to capture Protein-RNA probe complexes and unbound RNA probes respectively, were further sandwiched in dot blot assembly. The incubated mixture was drawn through slowly by vacuum. Following incubation, membranes were separated, air dried, and measured by autoradiography for 6 hr. After 6 hr, the dots from membranes were cut out and corresponding radiation was quantified using a scintillation counter.

Co-immunoprecipitation assay {#s3-15}
----------------------------

C2C12 cells were expanded according to previously described methods. In brief, cells were thawed from a low passage number and expanded by splitting before 40% confluency. At 95--100% confluency, cells were infected with AdPABPC1, AdPABPC1~mRRM2~, or AdGFP virus at 5 × 10^9^ o.p.u and incubated for 4 days. After 4 days, the cells were washed with PBS and lysed on ice in lysis buffer (50 mM HEPES \[pH 7.5\], 150 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1% Triton X-100, 5 mM dithiothreitol) supplemented with complete EDTA free protease inhibitor (Sigma-Aldrich, P0044) and phosphatase inhibitor (Thermo Scientific, 88666). Of cell lysate, 1--5 mg was incubated with 50% slurry of 200 μL of anti-Flag magnetic beads (Sigma-Aldrich, M8823) in each IP reaction and incubated at 4°C for 6 hr. After washing, the proteins were separated by 8% SDS-PAGE, transferred to PVDF membranes, and detected with anti-eIF4G1 antibody (\#2617, Cell Signaling Technology).

Adenovirus design and use {#s3-16}
-------------------------

Adenovirus was produced using the methodology as previously described ([@bib5]). Briefly, ORF encoding FLAG-tagged PABPC1 and PABPC1mRRM2 were cloned into the p-Adeno-X-ZsGreen1 vector (Clonetech, 632267) using the In-Fusion kit (Clonetech, 639646) as per the manufacturer's instructions. High-titer adenoviruses were generated by transfecting Ad-293 cells (\~70% confluent) in T-25 flasks with linearized recombinant adenoviral plasmid using Mirus TransIT-2020 reagent. Virus was harvested once a cytopathic effect was observed. Next, two viral amplification steps were performed and the viral particles were purified using a CsCl gradient accurding to the Adeno-X Adenoviral System 3 user manual. After purification of viral particles, the titer was determined by ultraviolet spectrophotometry at 260 nm. Neonatal cardiomyocytes cultured in NW media were transfected with siRNA target the 3'UTR of endogenous *Pabpc1*. After 6 hr, the cardiomyocytes were infected with 5 × 10^9^ o.p.u. of Ad-PABPC1, Ad-PABPC1~mRRM2~, or Ad-GFP adenovirus. Cells were washed and treated with 20 nM Isoproterenol following a 12 hr incubation with virus. After 36 hr of Isoproterenol treatment, cells were collected to harvest protein and RNA for further analysis.

Protein synthesis rate, Click chemistry {#s3-17}
---------------------------------------

Protein synthesis was measured using the L-homopropargylglycine (HPG) Click-iT (ThermoFisher, C10428) metabolic labeling reagents according to the manufacturer's protocol. Briefly, cultured neonatal cardiomyocytes were washed twice with warmed PBS and incubated in methionine-free DMEM supplemented with Iso or T3 for 1 hr. The medium was replaced with methionine-free DMEM to which 50 μM of the methionine analog HPG was added. Cells were again treated with same concentration of Iso or T3 and incubated for 60 min for incorporation of the AHA into nascent proteins with or without Iso/T3. After incubation, the dishes were rinsed twice. Newly synthesized proteins labeled with Click-iT HPG were conjugated with the carboxytetramethylrhodamine alkyne (TAMARA) using the Click-iT TAMRA Protein Analysis Kit (Cat. no. C33370). Protein samples were separated on 10% SDS-PAGE and was visualized using 532 nm excitation. The gel was subsequently stained with Coomassie blue for normalization.

RNA-FISH {#s3-18}
--------

To determine the cellular location of *Pabpc1* mRNA, we performed RNA-FISH on undifferentiated and differentiated C2C12 cells using the Stellaris RNA-FISH kit (Biosearch Technologies). In brief, 48 fluorescently labeled oligonucleotide probes targeting *Pabpc1* mRNA were designed using the custom Stellaris Probe Designer ([Supplementary file 1](#SD5-data){ref-type="supplementary-material"}). Undifferentiated and differentiated C2C12 cells were fixed in a 3.7% formaldehyde buffer in 1X PBS. The cells were then permeabilized using 70% ethanol for 48 hr at 4°C. All subsequent steps were performed in the dark to minimize loss of fluorescent signal. Hybridization with the probes was performed by washing the cells with Stellaris Wash Buffer A before incubating overnight at 37°C with hybridization buffer containing the probe set or hybridization buffer only as a negative control. Cells were then washed for 1 hr with Wash Buffer A before incubating with NucBlue (ThermoFisher Scientific) nuclear stain for 5 min. After incubation with DAPI, cells were washed in Wash Buffer B for 5 min and mounted with CC/Mount (Sigma-Aldrich). Images were obtained using a Zeiss LSM 700.

RNAse H digestion and northern blotting {#s3-19}
---------------------------------------

To assess the *Pabpc1* poly(A) tail lengths by northern blot, we mixed total RNA with 0.5 μM DNA oligonucleotides that hybridize to PABPC1 or GAPDH in 15 μL. Where indicated, oligo-dT40 was also included at 0.5 μM. After incubation at 65° for 5 min and chilling on ice, the following components were added to the reaction in 30 μL total volume: 1X RNase H buffer (Promega), 10 mM DTT, 15 ng/μL poly(A) (Sigma), 20 U RNasin (Promega), and 1 U RNase H. The reaction proceeded at 37° for 2 hr and was stopped by addition of 270 μL of G-50 buffer (0.25% SDS, 0.3 M NaOAc, 20 mM Tris pH 6.8, and 2 mM EDTA). RNA was isolated by standard phenol:chloroform:isoamyl alcohol (25:24:1) extraction followed by ethanol precipitation. Northern blots were performed as previously described ([@bib6]). RNA probes were generated by incorporation of ^32^P-UTP into in vitro transcribed RNAs using T7 templates generated by PCR.

Poly(A) tail fractionation {#s3-20}
--------------------------

This protocol was based on one previously reported ([@bib29]). Herein, a 1X SSC solution contains 150 mM NaCl and 15 mM sodium citrate at pH 7.0. Briefly, 100 μL of GTC buffer (4M guanidine thiocyanate, 25 mM sodium citrate, pH 7.1) was mixed with \~5--15 μg RNA, 2 μL β-mercaptoethanol, and 3.75 μL of 50 μM biotinylated oligo dT (Promega) in a final volume of \~115 uL. To this mixture, 209 μL of dilution buffer (3X SSC, 5 mM TrisHCl pH 7.5, 0.5 mM EDTA, 0.125% SDS, 5% β-mercaptoethanol) was added. The samples were heated to 70°C for 5 min and centrifuged at 12,000 x g at room temperature. The supernatant was then mixed with MagneSphere Streptavidin paramagnetic particles (Promega; 150 μL of manufacturer's slurry) that had been washed three times with 0.5X SSC and Igepal-CA-630 was added to 0.1%. The RNA and dT and bead solution was allowed to bind for 15 min at 25°C while rotating and subsequently washed three times with 0.5X SSC containing 0.1% Igepal-CA-630. Elutions were performed by incubation of the beads in 400 μL SSC at the indicated concentration plus 0.1% Igepal-CA-630 for 5 min at 25°C. RNA was isolated by standard phenol:chloroform:isoamyl alcohol (25:24:1) extraction followed by ethanol precipitation. RNase T1 treatment and poly(A) tail northern blots were performed as previously described^10^. After standardization the elution conditions were then used on 2.5 μg of total RNA from heart tissue. In order to elute short poly(A) tailed mRNA \[Poly(A)\<30\], we used elution buffer containing 0.075X SSC while for eluting long polyA mRNA \[poly(A)\>30\] we used nuclease-free water. Eluted sample was purified and used for cDNA synthesis and downstream qPCR analyses.

Statistics {#s3-21}
----------

All quantitative experiments (for example, qPCR, Western blots, cell areas and counts) have at least three independent biological repeats. Differences between groups were examined for statistical significance using Student's *t*-test (for two groups), or one-way ANOVA plus Dunnett's post-hoc test (for more than two groups) using the GraphPad Prism 6 Software (RRID: [SCR_002798](https://scicrunch.org/resolver/SCR_002798)). Results were expressed as mean ± s.d., unless otherwise specified. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001 were considered statistically significant.
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Thank you for submitting your article \"Poly(A) tail length regulates PABPC1 expression and tunes translation in the heart\" for consideration by *eLife*. Your article has been favorably evaluated by Fiona Watt (Senior Editor) and three reviewers, one of whom, Nahum Sonenberg (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors show that PABPC1 expression in the heart (cardiomyocytes) is regulated to support active translation during development and down-regulated to match the significantly reduced rate of translation observed in adult heart. The down-regulation of PABPC1 expression appears to be related to altered poly(A) status of the *Pabpc1* mRNA. The authors further reveal that PABPC1 expression is reestablished during exercise-induced hypertrophy to support the translation required for cardiomyocyte hypertrophy and that, in a model of chronic adult PABPC1 expression, that this adult PABPC1 expression does not appear to have obviously deleterious consequences.

The paper is of great interest to the readers in the fields of translational control and cardiology. In general, this is a high-quality study that reveals a previously unknown physiological role for PABPC1 and is therefore of significant interest. The data is generally of high quality and the interpretation is reasonable.

Essential revisions:

1\) The authors state that they uncovered a poly(A)-based regulatory mechanism. There is a change in poly(A) tail length of *Pabpc1* mRNA, but data supporting a mechanistic role for this is missing. The questions that need to be answered are: What is the poly(A) tail status of the reporter mRNAs in C2C12 cells? What is the poly(A) status of *Pabpc1* mRNA in the different fractions across the gradient in E18 and adult heart? Is there a correlation between polysome association and poly(A) tail length, does poly(A) tail length drive polysome association or does it protect/enhance deadenylation? It needs to be clear whether changes in poly(A) tail length are a cause, effect or bystander. The experiment in RRL is not informative and should be deleted.

2\) Polysome profiles should be provided for the PABPC1 overexpression in mouse heart experiment to establish that this does indeed result in a change in translational utilization of mRNAs as posited.

3\) Delete [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"} -- \[or provide validation for the antibody\]; [Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"} -- *Pabpc1* mRNA levels should not be plotted on a log scale -- which masks any changes between fetal and adult heart. For [Figure 1E-J](#fig1){ref-type="fig"} -please provide single channel images in main/supplemental figures; clarify how protein levels were quantified (e.g. in WB- digital acquisition system), some stats are missing in places e.g. [Figure 1D,B](#fig1){ref-type="fig"}, [Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}.

4\) [Figure 2](#fig2){ref-type="fig"}: If the model of poly(A) tail length regulation is correct, then one would expect that polysome-associated *Pabpc1* mRNA would increase under stress conditions. The addition of these experimental data would bolster the overall conclusion of the study.

5\) Results and Discussion, seventh paragraph, [Figure 3](#fig3){ref-type="fig"} and Figure S3---figure supplement 2A. Although PABPC1 plays an important role in mRNA stability in addition to translation, there are increased levels of *Acta1, Myh7* and *Anp* mRNAs in *Pabpc1*-knockown (KD) cells. Why are these mRNAs so stable in the absence of PABPC1?

6\) Results and Discussion, in the conclusion, the authors need to address the question as to why is the *Pabpc1* mRNA harboring a short poly(A) tail stable in mature cardiomyocytes in the absence of PABPC1?

10.7554/eLife.24139.022

Author response

*Essential revisions:*

*1) The authors state that they uncovered a poly(A)-based regulatory mechanism. There is a change in poly(A) tail length of PABPC1 mRNA, but data supporting a mechanistic role for this is missing. The questions that need to be answered are: What is the poly(A) tail status of the reporter mRNAs in C2C12 cells?*

We appreciate the reviewer's suggestion to measure poly(A) tail lengths of *Pabpc1* reporter mRNAs. This is an interesting experiment, but somewhat artificial because our reporters contain strong heterologous polyadenylation elements as part of the plasmid backbone. Instead, we measured the poly(A) tail status of endogenous *Pabpc1* mRNAs in C2C12 cells. The poly(A) tail length data obtained were consistent with reduced PABPC1 protein levels seen during myoblast-to-myotube differentiation ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}) such that *Pabpc1* mRNAs were significantly deadenylated in myotubes when compared to myoblasts. These new data are added to the revised [Figure 2D](#fig2){ref-type="fig"}.

*What is the poly(A) status of PABPC1 mRNA in the different fractions across the gradient in E18 and adult heart? Is there a correlation between polysome association and poly(A) tail length, does poly(A) tail length drive polysome association or does it protect/enhance deadenylation? It needs to be clear whether changes in poly(A) tail length are a cause, effect or bystander.*

We have addressed this concern of the reviewer to provide further evidence for the correlation of *Pabpc1* poly(A) tail length and polysome association. An additional experiment measuring *Pabpc1* mRNA levels in short and long poly(A) tail fractions from polysome gradients has been added. In the neonatal heart, *Pabpc1* has long poly(A) tail length and associates exclusively with polysomes, whereas in the adult heart most *Pabpc1* mRNAs are short-tailed and associate with monosome and RNP fractions ([Figure 2E](#fig2){ref-type="fig"}). Poly(A) tail length of *Gapdh* mRNAs remain unchanged and primarily associate with polysomes at both developmental stages ([Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). Thus, these results point towards a causal effect of poly(A) shortening in suppressing *Pabpc1* translation in the adult heart.

*The experiment in RRL is not informative and should be deleted.*

As requested, we have removed the RRL in vitro translation data from the revised [Figure 2](#fig2){ref-type="fig"}.

*2) Polysome profiles should be provided for the PABPC1 overexpression in mouse heart experiment to establish that this does indeed result in a change in translational utilization of mRNAs as posited.*

We appreciate the reviewer's suggestion to demonstrate the effect of PABPC1 re-expression on translation. However, we feel that polysome profiles are, by nature, qualitative and believe that our in vivo experiment utilizing the SUnSET method in PABPC1 re-expressing mice ([Figure 5K](#fig5){ref-type="fig"}) is not only quantitative, but also more informative regarding the impact of PABPC1 on global translation in the heart. The SUnSET assay has become widely accepted in the field to measure protein synthesis and has been previously demonstrated to match polysome traces (Genes Dev. (2016) 30:1-6; Nat Commun (2016) 11776; FASEB J (2017) 30; 2: 798-812).

*3) Delete [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"} -- \[or provide validation for the antibody\].*

Anti-PABPC1 antibody (Abcam ab21060) used in the Human protein atlas database (see <http://www.proteinatlas.org/ENSG00000070756-PABPC1/antibody>) has been previously validated to specifically cross-react with human PABPC1. siRNA-based validation of this antibody is available in J Virol. 2013 Jan;87(1):243-56.

*[Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"} -- PABPC1 mRNA levels should not be plotted on a log scale -- which masks any changes between fetal and adult heart.*

Thank you for raising this point. We have revised the [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} by plotting the PABPC1 mRNA and protein level data on a normal scale in the graph.

For [Figure 1E-J](#fig1){ref-type="fig"} -please provide single channel images in main/supplemental figures.

As requested, we have now provided the single channel images in the [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.

Clarify how protein levels were quantified (e.g. in WB- digital acquisition system).

We have expanded the description of methods used to quantify the protein levels. Briefly, the blots were treated with an ECL substrate, visualized on a ChemiDoc digital acquisition system, and quantified using Image Lab Software.

*Some stats are missing in places e.g. [Figure 1D,B](#fig1){ref-type="fig"}, [Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}.*

We thank the reviewers for pointing out this oversight. We have now added the statistics, *p* values and *n* numbers to [Figure 1B](#fig1){ref-type="fig"} and [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}. The western blot data in [Figure 1D](#fig1){ref-type="fig"}, is derived from a single pool of fetal and adult human heart protein samples and this information is provided under the Methods section.

*4) [Figure 2](#fig2){ref-type="fig"}: If the model of poly(A) tail length regulation is correct, then one would expect that polysome-associated Pabpc1 mRNA would increase under stress conditions. The addition of these experimental data would bolster the overall conclusion of the study.*

We understand the reviewer's curiosity about the increase in polysome association of *Pabpc1* mRNA under stress conditions. These lines of investigations are logical extensions of our work, which we will be entertaining and testing in the future but they fall outside the scope of this current study.

*5) Results and Discussion, seventh paragraph, [Figure 3](#fig3){ref-type="fig"} and Figure S3---figure supplement 2A. Although PABPC1 plays an important role in mRNA stability in addition to translation, there are increased levels of Acta1, Myh7 and Anp mRNAs in PabpC1-knockown (KD) cells. Why are these mRNAs so stable in the absence of PABPC1?*

We thank the reviewers for raising this important point. As has been previously reported, we believe that increased mRNA abundance of *Acta1, Myh7* and *Anp* in cardiomyocytes after Isoproterenol or T3 stimulation is due to increased transcription of these hypertrophy markers (J Clin Invest. (2008) 118(1): 124-132; Biochim Biophys Acta. (2013) 1832 (12): 2403-13). However, as the reviewer pointed out, it is interesting to note that the increased mRNA abundance of *Acta1, Myh7* and *Anp* is maintained even in PABPC1 depleted cells after Iso or T3 stimulation. These results imply that PABPC1 knockdown does not (i) interfere with the transcriptional regulatory circuits; and/or (ii) have a major impact on the mRNA stability of these genes. We have added this discussion to the revised manuscript.

*6) Results and Discussion, in the conclusion, the authors need to address the question as to why is the Pabpc1 mRNA harboring a short poly(A) tail stable in mature cardiomyocytes in the absence of PABPC1?*

Thank you for this comment. It is indeed interesting that in spite of harboring short poly(A) tails, *Pabpc1* mRNA is stable in mature cardiomyocytes. This stabilization could be imparted through binding of *trans*-acting factor(s), due to the presence of RNA structural element(s), or RNA modifications that may inhibit further recruitment/activity of deadenylases. We have mentioned these possibilities now in the Discussion section.

[^1]: These authors contributed equally to this work.
